Evotec and Bristol Myers Squibb Expand Proteomics Partnership with $50 Million Upfront

Oct 23, 2024, 06:02 AM

Evotec SE and Bristol Myers Squibb have announced an expansion of their proteomics partnership, which will now include a new molecular glue-based collaboration. This collaboration begins with a $50 million upfront payment from Bristol Myers Squibb to Evotec. The partnership aims to build a molecular glue-based pipeline, leveraging the success of previous deals between the two companies. The new collaboration focuses on non-protac degraders.